Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances

Gwilym J Webb, Gideon M Hirschfield

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)
268 Downloads (Pure)

Abstract

In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights.
Original languageEnglish
Pages (from-to)76-78
Number of pages3
JournalNature Reviews. Gastroenterology & Hepatology
Volume14
Issue number2
Early online date11 Jan 2017
DOIs
Publication statusPublished - Feb 2017

Keywords

  • obeticholic acid
  • Primary biliary cholangitis
  • cholangiocytes
  • Cholestatic liver disease
  • biliary

Fingerprint

Dive into the research topics of 'Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances'. Together they form a unique fingerprint.

Cite this